"Virginia Heart is the leader in cardiovascular care in the Washington D.C. metropolitan area and our patients have been putting their trust in us for over 30 years. Our Virginia Heart team of physicians and professionals is dedicated to providing the highest standards of care using the most advanced diagnostic procedures and treatments, ensuring our patients with the best possible outcomes and quality of life."

During the past decade, Virginia Heart conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 7 clinical trials were completed, i.e. on average, 63.6% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 4 clinical trials were completed. i.e. 57.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Virginia Heart" #1 sponsor was "Abbott Medical Devices" with 2 trials, followed by "Amgen" with 2 trials sponsored, "Bayer" with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Virginia Heart" #1 collaborator was "Duke Clinical Research Institute" with 2 trials as a collaborator, "Pfizer" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator and "Medtronic" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Virginia Heart" are "Atrial Fibrillation" (3 trials), "Cardiovascular Disease" (3 trials), "Heart Failure" (3 trials), "Stroke" (2 trials) and "ASCVD" (1 trials). Many other conditions were trialed in "Virginia Heart" in a lesser frequency.

Most popular intervention types in "Virginia Heart" are "Drug" (10 trials), "Device" (3 trials), "Other" (3 trials), "Combination Product" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Apixaban" (3 trials), "bococizumab (PF-04950615)" (2 trials), "ACUITY Spiral Left Ventricular Lead" (1 trials) and "Acetylsalicylic acid" (1 trials). Other intervention names were less common.

The vast majority of trials in "Virginia Heart" are 17 trials for "All" genders.

Currently, there are NaN active trials in "Virginia Heart". undefined are not yet recruiting, 2 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 6 completed trials in Virginia Heart, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Virginia Heart, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".